Navigation Links
Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
Date:10/27/2009

Bio-activated Prodrug Demonstrates Significant Reduction in Incidence of GI Ulcers and Erosions

SAN DIEGO, Oct. 27 /PRNewswire/ -- Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions. In the study, subjects receiving LT-NS001 experienced a 78 percent reduction in the rate of gastric ulcers, and fewer gastric and duodenal erosions, when compared with subjects receiving Naprosyn(®) (naproxen). The LT-NS001 prodrug is unique among non-steroidal anti-inflammatory drugs (NSAIDs) as it is pharmacologically inactive as a COX inhibitor in the GI tract, but once absorbed into the bloodstream, it is converted rapidly to naproxen. LT-NS001 has been engineered to reduce the GI safety risks associated with NSAIDs. Results were announced here at the American College of Gastroenterology's (ACG) Annual Scientific Meeting and presented by Jay L. Goldstein, MD, FACG, Professor of Medicine at the University of Illinois at Chicago, who was the lead investigator for the study.

"The positive results of this study challenge the conventional wisdom regarding NSAID-induced gastrointestinal injury, which physicians generally believe can be driven by systemic exposure to the drug. This study demonstrates that a novel mechanism for NSAID therapy, namely a bio-activated prodrug technology, can provide a significant level of improvement in GI safety, and that may be surprising to many physicians," said Peter A. Lankau, Chief Executive Officer of Logical Therapeutics. "This study brings us one step closer to fulfilling a significant unmet medical need for an NSAID with an improved GI toxicity profile and we look forward to continuing the clinical development of LT
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NEW YORK , June 18, 2013 JDRF ... ) are accelerating the development of new products that combine ... new collaboration announced today. This new, three-year commitment is an ... (T1D). Many patients with T1D not only take ... to be placed in the body for a number of ...
(Date:6/18/2013)... , June 18, 2013 Today, ... Inc. (NASDAQ: GILD ), Health Management Associates Inc. ... IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ... access these reports free of charge - including full price ... below. Gilead Sciences, Inc. Research Report ...
(Date:6/18/2013)... , June 18, 2013 Remedy ... for healthcare and life sciences research, today announced ... Administration (GSA) IT Schedule 70 supply contract (GS-35F-367AA, ... to provide innovative IT solutions to government agencies ... with this contract, Remedy has placed its products ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4
... Dec. 14 Results from a Phase 3 ... were treated previously with,an anthracycline in the adjuvant ... progression (TTP) and overall response rates after,receiving a ... as compared to docetaxel alone. , ...
... bioMerieux company,that discovers, develops and commercializes new molecular ... studies using the company,s,molecular breast cancer assay to ... from the studies were presented this week at ... The Theros Breast ...
Cached Medicine Technology:Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 2Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 3Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 4Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 5Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 6Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 7Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer 8Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 2Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 3Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium 4
(Date:6/18/2013)... Consumer injury attorney Michael J. Evans announced ... launched a new website for people who believe they ... is http://www.DialysisLawsuitAttorneys.com . , "My litigation partners and ... services to people who may have been injured by ... may have suffered injuries due to some other form ...
(Date:6/18/2013)... 2013 "What if adding one simple ... boost your health and well-being? Well, there is something ... Beauty®. "It is called Skin Brushing ." , ... a lost art. Now, people are rediscovering this great ... and so do certain health conscious people. Sublime Beauty® ...
(Date:6/18/2013)... 2013 Looking for a way to break ... life? , IWALKAWAKE is a guide to unlocking one’s ... Botha, it focuses on harnessing the powerful and abundant spiritual ... out a nine-step guide to finding one’s true purpose and ... must go through to reach their true potential. The awakenings ...
(Date:6/18/2013)... SEATTLE, WA—A Washington state resident filed ... claiming he fell ill with a hepatitis A infection ... blend. The complaint was filed in Snohomish County ... Seattle-based law firm that has filed 14 previous ... complaint, Brian Brothers consumed “Townsend Farms Organic Antioxidant Blend” ...
(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...
Breaking Medicine News(10 mins):Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 2Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 3Health News:Fresenius, Maker of Recalled Dialysis Drugs GranuFlo And NaturaLyte, Is Back In The News With Problems At Its Dialysis Center In Bessemer, Alabama 4Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
... A growing number of Americans know about chronic obstructive pulmonary ... disease, a new survey has found. According to the ... knew about COPD, a 4 percent increase from 2008. Awareness ... results were released this week by the U.S. National Heart, ...
... (Geneva, Switzerland) A Pneumonia Report Card released today ... of the Global Coalition against Child Pneumonia reveals where ... coverage for the life-saving interventions that can prevent, protect ... is the world,s leading infectious killer of young children, ...
... A new study from researchers in Colorado shows that women ... a screening colonoscopy than those who were not offered this ... to be common among women. In this study, a patient ... screening colonoscopy can be increased by offering women the option ...
... 11, 2010 The November 2010 issue of the ... Journal of the American Congress of Rehabilitation Medicine, has ... injury (TBI) that will accelerate future research in the ... injury, how it is measured and classified, treatment and ...
... 11 (HealthDay News) -- Diabetes is a leading cause of ... the risk factors and what they can do to prevent ... "Diabetes is a chronic condition that can cause serious ... kidney failure and nervous system damage," ACP President Dr. J. ...
... release is available in French . , Montreal, ... should receive an additional cardiac test when undergoing diagnosis for ... University, the Universit du Qubec Montral and the Montreal ... in the Journal of Cardiopulmonary Rehabilitation and Prevention , ...
Cached Medicine News:Health News:Awareness of COPD Growing, But More Lung Testing Urged 2Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 2Health News:Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 2Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 3Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 4Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 5Health News:Consensus on TBI and PTSD will accelerate future research and improve patient care 6Health News:Are You at Risk of Developing Diabetes? 2Health News:Additional cardiac testing vital for patients with anxiety and depression 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: